End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.
A novel liquid biopsy test, which uses two circulating proteins, appears to be effective for diagnosing these two major liver conditions, according to a new study.